2017
Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer
O’Connor M, Morrow MMB, Hunt KN, Boughey JC, Wahner-Roedler DL, Conners AL, Rhodes DJ, Hruska CB. Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. EJNMMI Research 2017, 7: 5. PMID: 28091980, PMCID: PMC5237435, DOI: 10.1186/s13550-017-0255-6.Peer-Reviewed Original ResearchBreast cancerBenign lesionsMolecular subtypesBreast lesionsTumor molecular subtypeOverall diagnostic performancePathologic sizeAnalyzable patientsTumor extentMalignant tumorsLesion extentBlinded fashionLesion sizeSestamibiMolecular breastPatientsLesionsAlternative radiotracersLesion uptakeAssessment scoresROC analysisCancerInterest analysisDiagnostic performanceExamination one
2015
Factors Influencing the Uptake of 99mTc-Sestamibi in Breast Tissue on Molecular Breast Imaging
O’Connor M, Hruska CB, Tran TD, Swanson T, Conners AL, Jones K, Rhodes DJ. Factors Influencing the Uptake of 99mTc-Sestamibi in Breast Tissue on Molecular Breast Imaging. Journal Of Nuclear Medicine Technology 2015, 43: 13-20. PMID: 25613340, DOI: 10.2967/jnmt.114.150128.Peer-Reviewed Original ResearchConceptsMolecular breast imagingBreast tissuePrandial statusOptimal patient preparationPeripheral blood flowBody surface areaCounts/Type of interventionBreast imagingPatient heightPeripheral warmingStudy groupBlood flowSestamibiBreast activityPatient preparationFed stateCount densityMetabolic statusReference groupOblique viewMediolateral oblique viewTissueInterventionBreast thickness